Children who inherit genetic mutations from parents with early-onset Alzheimer’s typically show signs of dementia at the same ...

In obesity, Lilly removed a dual amylin calcitonin receptor agonist (DACRA) from its phase 1 pipeline. Lilly got into DACRAs by partnering with KeyBioscience in 2017. At one time, the Big Pharma was ...

As Alphabet expands its AI efforts, the company expects to increase investments in capital expenditure (capex) for technical ...

Google Services revenues for the quarter, up 10% from the previous year, thanks in large part to strong growth in Google ...

The new CFO, Anat Ashkenazi, you might remember, she was at Eli Lilly, she tells a terrific story. We’ll be listening for anything about the growth of Google’s cloud infrastructure business.

With its offering of tirzepatide (branded as Mounjaro and Zepbound), Eli Lilly and Co. (NYSE: LLY) was another key pharma player in this new type of treatment for diabetes and obesity.

INDIANAPOLIS - Eli Lilly and Company (NYSE: NYSE:LLY) announced today that Anat Ashkenazi has resigned from her position as Chief Financial Officer (CFO) to explore a new career... ByInvesting.com ...

Not long after reporting phase 2 data for one of its obesity candidates that appeared to put it on par with Eli Lilly’s Zepbound, Kailera Therapeutics is preparing for an eventual market launch ...

In a report released today, Terence Flynn from Morgan Stanley reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price target of $1,146.00. The company’s shares closed ...

On an investment spree with billions of dollars’ worth of projects ongoing globally, Indianapolis-based Eli Lilly and Company chose Kenosha County for its latest – and one of its largest ...